RRC ID |
36972
|
著者 |
Tomita O, Iijima K, Ishibashi T, Osumi T, Kobayashi K, Okita H, Saito M, Mori T, Shimizu T, Kiyokawa N.
|
タイトル |
Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1.
|
ジャーナル |
Leuk Res
|
Abstract |
We introduced SNX2-ABL1, a novel ABL1-related chimeric transcript lacks SH3 and SH2 domains, into murine Ba/F3 cells and compared their function with that of BCR-ABL1. After the expression of SNX2-ABL1 proteins, Ba/F3 cells acquired an ability to proliferate in an IL-3-independent manner. Upon treatment with both imatinib and dasatinib, BCR-ABL1-expressing Ba/F3 cells underwent rapid apoptosis, whereas SNX2-ABL1-expressing Ba/F3 cells showed poorer sensitivity toward these TKIs and could proliferate in the presence of a low dose of dasatinib. Therefore, other TKIs with a more selective effect against this chimeric kinase should be used for the treatment of patients with SNX2-ABL1+ ALL.
|
巻・号 |
38(3)
|
ページ |
361-70
|
公開日 |
2014-3-1
|
DOI |
10.1016/j.leukres.2013.11.017
|
PII |
S0145-2126(13)00418-9
|
PMID |
24367893
|
MeSH |
Animals
B-Lymphocytes / drug effects*
B-Lymphocytes / immunology
B-Lymphocytes / pathology
Benzamides / pharmacology
Cell Line
Dasatinib
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm
Fusion Proteins, bcr-abl / genetics*
Fusion Proteins, bcr-abl / immunology
Gene Expression Regulation, Leukemic / drug effects*
Genetic Vectors
Humans
Imatinib Mesylate
Interleukin-3 / pharmacology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
Mice
Piperazines / pharmacology
Protein Kinase Inhibitors / pharmacology*
Protein Structure, Tertiary
Pyrimidines / pharmacology
Retroviridae / genetics
Sorting Nexins / genetics*
Sorting Nexins / immunology
Thiazoles / pharmacology
Transfection
|
IF |
2.214
|
引用数 |
13
|
WOS 分野
|
ONCOLOGY
HEMATOLOGY
|
リソース情報 |
ヒト・動物細胞 |
WEHI-3(RCB0035) |